Tuberculosis (TB) control and eradication efforts in India started in the 1950’s and have been gaining s...
Trivitron Healthcare, a global medtech organisation, has announced the launch of Kiran Smart Track, India&rsqu...
IAN Group, the country’s single largest early-stage investment platform, has invested in Rymo Technologi...
Corning Incorporated has introduced the Corning Low-Flow Reactor System 2 as the latest product line available...
Can India’s CDMOs Lead the Next Biopharma Wave?
India’s Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3–3.5 billion today to $22–25 billion by 2035, noted Boston Consulting Group (BCG). While small molecules continue to form the backbone of manufacturing, new opportunities are emerging in biologics, antibody drug conjugates (ADCs), gene therapies, and RNA therapeutics. As India gears up for this next phase of expansion, what challenges stand in the way, and how is the industry preparing to address them? Let’s find out.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
